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Background: Idiopathic thrombotic thrombocytopenic purpura (TTP) is a rare hematological emergency characterized
by the pentad of microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, renal injury, and
fever that is invariably fatal if left untreated. Prompt intervention with plasma exchange minimizes mortality and is the
cornerstone of therapy. Rare reports have described “pseudo-TTP” driven by extreme hematologic abnormalities resulting
from deficiency of vitamin B12. Distinguishing between these entities can pose a diagnostic and therapeutic challenge.
Case presentation: A 77 year old female presented with altered mental status, renal insufficiency, thrombocytopenia
and evidence of microangiopathic hemolytic anemia, suggesting TTP. Workup demonstrated macrocytosis and
reticulocytopenia, and B12 level was unmeasurably low. Other elements of her clinical presentation, including volume loss
and bleeding suggested a multifactorial pathogenesis could be contributing to her laboratory abnormalities, reducing
the likelihood that she had TTP. The risks and benefits of treating aggressively with therapeutic plasma exchange (TPE) for
TTP were considered given the diagnostic possibilities. The patient received TPE initially, with rapid de-escalation after her
clinical response suggested “pseudo-TTP” from B12 deficiency was the driving the process. B12 supplementation corrected
her hematologic abnormalities and she remains well two years after presenting.
Conclusions: TTP is a rare condition with fatal consequences if left untreated. Guidelines recommend TPE even
if there is uncertainty about the diagnosis of TTP. B12 deficiency is common, though not typically associated with severe
hematologic abnormalities. We compare the presenting characteristics of all thirteen cases of pseudo-TTP reported in the
literature with those from patients in case series of TTP to suggest a set of parameters that can help clinicians distinguish
between pseudo-TTP and TTP and guide decision making regarding intervention. Evaluation of all TTP cases
should include a B12, methylmalonic acid level and reticulocyte count. Reticulocytopenia suggests B12 deficiency. Finally
an LDH level above 2500 IU/L is relatively uncommon in TTP and should suggest consideration of B12 deficiency.
Keywords: TTP, pseudo-TTP, Anemia, Pernicious anemia, Schistocytes, CobalaminBackground
Idiopathic TTP (reviewed in [1]) is a rare hematological
emergency (four cases per million) driven by an inhibitory
autoantibody to the ADAMTS13 metalloproteinase caus-
ing the accumulation of unusually large von Willebrand
factor multimers. These multimers cause platelet aggrega-
tion and thrombi resulting in end organ damage. TTP is
characterized by the pentad of microangiopathic hemolytic* Correspondence: dbmartin@uw.edu
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Prompt intervention with TPE minimizes mortality, with
complete response rates of roughly 75 % [2, 3]. TPE, how-
ever, is also associated with considerable risks. A cohort
study of 302 consecutive patients from the Oklahoma
TTP-HUS registry over 15 years showed a 2.3 % mortality
rate and a 24 % rate of major complications secondary to
plasma exchange [4]. B12 deficiency (reviewed in [5]) is
seen in 4 % of older adults with a median age range
of 70 to 80, and is often missed due to its subtle clin-
ical manifestations. The classic hematologic changes seen
in B12 deficiency include macrocytic anemia and neutrophilis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Peripheral smear (60×) showing anisopoikilocytosis with
occasional teardrops cells and scattered schistocytes
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thrombocytopenia, and elevated serum lactate dehydrogen-
ase and bilirubin [6]. One study has shown that approxi-
mately 10 % of patients with symptomatic cobalamin
deficiency have significant hematologic manifestations in-
cluding pancytopenia, severe anemia, and microangiopathy
[7]. It should also be noted that patients undergoing bariat-
ric surgery are at risk for B12 deficiency and that the popu-
larity of this procedure is growing. In 2008, roughly 220,000
bariatric surgeries were performed in the United States, a
large fraction of which were gastric bypass procedures [8].
The prevalence of low vitamin B12 was found to be 11 %
one year after year after roux-en-Y gastric bypass [9]. In this
report we present a patient with a presentation concerning
for TTP with clinical features illustrating potential clinical
similarities between TTP and severe B12 deficiency.
Case presentation
A 77 year-old female was brought to a neighboring hos-
pital with altered mental status, having been found unre-
sponsive at home with evidence of bowel incontinence
and bloody diarrhea. The patient had been well until two
weeks prior to admission when she developed symptoms
of nausea, vomiting and diarrhea that progressively
worsened until the day of admission.
On presentation the patient was confused, afebrile and
moderately hypotensive. Initial hemoglobin was 55 g/L
with a mean corpuscular volume of 120 fL. Platelet
count was 40 × 109/L and white blood cell count was
5.9 × 109/L. Reticulocyte count was 3.4 % and corrected
reticulocyte count 1.2 %. The peripheral blood smear,
interpreted by the pathologist, showed anisocytosis,
poikilocytosis, and multiple schistocytes. Hypersegmen-
tation of neutrophils was not noted. Other pertinent
laboratory findings included a creatinine of 300 μmol/L,
lactate dehydrogenase (LDH) of 3981 IU/L, and INR >10
in the setting of warfarin use for a thrombosis four
months prior to admission. Her fibrinogen level was
4.44 g/L. The patient received 6 units of platelets, 3
units of packed red blood cells, and 3 units of fresh
frozen plasma and crystalloid support. She was treated
empirically with intravenous pantoprazole. Her blood
pressure normalized and mental status improved sub-
stantially although incompletely with these measures. A
vena cava filter was placed. B12 levels drawn on admis-
sion returned undetectable and she was given 1 mg B12
intramuscularly. Twenty four hours after admission, she
was referred to our hospital for emergent TPE for a
presumptive diagnosis of TTP given her altered mental
status, renal insufficiency, thrombocytopenia and evidence
of microangiopathic hemolytic anemia.
Upon arrival her hemoglobin had improved to 99 g/L
and platelet count to 60 × 109/L. Repeat peripheral
smear was notable for marked anisopoikilocytosis withoccasional teardrops cells and scattered schistocytes
Fig. 1. Haptoglobin was undetectable and LDH remained
elevated at 3360 IU/L. A direct Coombs test was negative.
Her INR was 1.3. Her creatinine had fallen to 152 μmol/L.
The fractional excretion of sodium and urinary sediment
were suggestive of pre-renal acute kidney injury/acute
tubular necrosis.
The responsiveness of the patient’s platelet count to
transfusion, improvement in renal function and plausi-
bility of B12 deficiency as an explanation called into
question the diagnosis of TTP. However, given the po-
tential adverse consequences delayed plasma exchange
in TTP, the decision was made to proceed with TPE. A
double lumen apheresis catheter was placed and she
received TPE for three consecutive days along with daily
intramuscular cobalamin. During this time, her LDH
fell dramatically, her mental status returned to baseline,
and her creatinine continued to decline. However her
hemoglobin and platelet count did not improve.
Given the lack of appreciable change in platelets and
hemoglobin after three days of TPE, the decision was
made to hold plasma exchange and observe. On hospital
day five (six days after starting therapy with B12), her
platelet count began to rise and normalized on hospital
day nine. LDH fell dramatically two days after starting
therapy and stabilized at a slightly elevated level
(~375 IU/L) after five days of therapy. Her creatinine
continued to fall and reached a stable baseline of
57 μmol/L on hospital day ten. Anti-intrinsic factor
antibody was later found to be positive. Her apheresis
catheter was removed on hospital day seven. Upper en-
doscopy demonstrated atrophic gastritis. Colonoscopy
showed left sided diverticulosis and internal hemorrhoids,
thought to be the source of her bleeding at presenta-
tion. She was discharged after 12 days on enoxaparin and
warfarin with the recommendation to remove the IVC fil-
ter in six months. Monthly B12 was recommended for life.
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normal. She remains in good health greater than one
year following discharge.
Discussion
This patient presented with findings highly suspicious for
TTP, but ultimately attributable to multiple coincident
causes that combined to produce this clinical scenario.
Her microangiopathic picture and thrombocytopenia were
attributable to severe B12 deficiency and volume and blood
loss from diarrhea and gastrointestinal bleeding (in the
setting of supratherapeutic anticoagulation) caused acute
kidney injury, and contributed to mental status changes.
This case presented a dilemma in which the potential life-
saving benefit of prompt therapeutic intervention for TTP
was balanced against the potential morbidity and mortality
of the intervention itself, given the possibility of a
masquerading processes. In this case the decision was
made to incur the upfront risk of TPE to avoid the
possibility of harm through delay of therapy for TTP.
Ongoing TPE was made contingent on evidence of
response or non-response.
In review of the literature, our patient is the fourteenth
described with B12 deficiency mimicking TTP and the
first where acute kidney failure complicated the differen-
tial diagnosis. Prior descriptions have used the term
pseudo-TTP to describe this clinical scenario. The char-
acteristics of six patients individually described in case
reports are summarized in Table 1. Seven other patients
have been described in a case series from a French refer-
ral center seen over a 10 year period [10, 11] with data
aggregated. The B12 deficient patients seen in this series
had an average platelet count of 73 × 109/L, ranging from
38 × 109/L to 130 × 109/L. They were all reticulocytopenic,
with absolute reticulocyte counts between 6.3 to 39.8
(109/L). The average LDH level was 7310 IU/L (range
1084–16,520 IU/L). Mean data is presented in Table 1.
The B12 levels ranged from 15 to 111 umol/l in this series.
Differentiating pseudo-TTP from TTP is potentially
challenging even if both are under consideration. A
number of parameters including renal function, MCV,Table 1 Characteristics of pseudo-TTP patients individually reported
Case Year Sex Age WBC (×109/L) HCT HGB PLT (n
1 1998 F 38 3.6 39 260
2 1999 F 68 3.2 32 110
3 2003 M 38 2.2 45 50
4 2008 M 48 6.3 50 380
5 2009 M 52 3.6 27 960
6 2011 F 31 4.2 57 420
Mean values from seven patients
Series 72 3.4 42 73neutrophil hypersegmentation, patient age, and LDH can
alter the pretest probability for either diagnosis. Review
of the reported cases in comparison to data from TTP
case series can provide some important “lessons learned”
and guidelines for workup of patients with TTP. None of
the 13 cases reported prior to ours described renal fail-
ure. However, renal failure is seen in only approximately
one half of patients in case series of TTP [12, 13]. An
elevated MCV should raise the possibility of B12 defi-
ciency. However, the MCV was in the normal range in
three of the reported cases, presumably due to the effect
of schistocytes in calculating the MCV. Neutrophil
hypersegmentation is frequently seen in B12 deficiency,
and should raise the suspicion for a nutritional defi-
ciency [6]. The measurement of B12 can be confounded
by the administration of plasma and “normal” levels
should be interpreted cautiously if drawn after initiating
TPE. In case 4, a B12 level drawn after TPE was initiated
was normal. However, the methylmalonic acid level was
extremely elevated at 25,417 umol/l and ultimately diag-
nostic [14]. Patient age can help guide thinking because
the median age of patients with B12 deficiency is 70 to
80 while two large series have shown that only fifteen
percent of patients presenting with TTP are over the age
of 60 years [15, 16].
A number of the pseudo-TTP case descriptions have
suggested that very high levels of LDH are suggestive of
B12 deficiency rather than TTP. Reports dating back
50 years have demonstrated unusually high levels of
LDH in megaloblastic anemia, far in excess of that seen
congenital and acquired hemolytic anemia. In two series
of 27 and 16 patients with pernicious anemia, the mean
LDH was 5360 IU/L and 3802 IU/L respectively with
maximal values of 15,900 IU/L and 11,000 IU/L seen
[17, 18]. These levels were much higher than those of
the control groups with other types of hemolytic
anemias. A reduction in LDH was observed after 4
to 6 days after B12 therapy. Accordingly, in 1961
Gronvall concluded “Values of LDH exceeding 3000
U./ml./min. in anemia argue strongly for pernicious
anemia” [17]. The etiology of the high values wasin the literature and averages from a case series
adir) (×109/L) LDH (IU/L) MCV (fL) Retic × 109/L TPE Ref
5700 102 20 NO [22]
7900 112 34 YES [23]
19,384 90 10 YES [24]
8988 80 13 YES [14]
4604 107 31 NO [25]
4579 110 NR YES [26]
7310 111 13 [10]
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LDH isoenzyme analysis [19].
The range of LDH levels seen in TTP case series is
wide and partially overlaps with those reported for
pseudo-TTP associated with B12 deficiency. The largest
series are summarized as follows: In 36 patients with
TTP seen at Washington University, the mean LDH was
939 IU/L, with a range from 328 to 28,000 IU/L. Thirty
two of these 36 patients had an LDH of less than
2000 IU/L and 35 of 36 had LDH less than 3000 IU/L
[13]. The single patient with LDH of 28,000 was found
to have an ADAMTS13 level of 74 %. In 100 patients
seen at the Cleveland Clinic with TTP, the mean +/− SD
of LDH was 1338 +/− 945 IU/L [16]. Findings in 72
cases from Johns Hopkins showed a median LDH
concentration of 1184 IU/L with an interquartile range
of 152 to 5950 IU/L [20]. The 261 patients reported in
the Oklahoma registry [21] were divided according to
ADAMTS13 levels. For 201 patients with ADAMSTS13
levels equal to or above 10 %, the median LDH was
1090 (range 114 to 12,587), and for 60 patients with
ADAMSTS13 levels below 10 %, the median LDH was
1407 (range 256 to 3909). Thus, it can be concluded that
most patients with TTP will have LDH levels below
2500 IU/dl, but a minority of patients, including those
with ADAMTS13 levels below 10 % (indicating bona
fide TTP), have LDH values that exceed this threshold.
Thus, an LDH value above 2500 IU/dl is seen infre-
quently in this disorder and should raise the possibility
of pseudo-TTP associated with B12 deficiency.
The parameter that is most helpful in differentiating
pseudo-TTP from TTP is the absolute reticulocyte count.
The French series above noted reticulocytopenia in all
seven patients reported. The reticulocyte counts in the
individual cases were all inappropriately low for the level
of anemia seen. The patient seen at our institution had a
low corrected reticulocyte count of only 1.2 %. Thus,
the absence of a brisk reticulocytosis should alert the
provider to the possibility of nutritional deficiency driving
the microangiopathy.
Conclusions
Pseudo-TTP from B12 deficiency should be among the
differential diagnoses of patients presenting with micro-
angiopathic hemolytic anemia. Its resemblance to TTP is
close enough that many of the reported cases have re-
ceived TPE. It is possible that some of the cases in TTP
series were actually pseudo-TTP given that it can
present with a normal B12 level and normal MCV. Our
literature review suggests that routine evaluation of sus-
pected TTP cases should include a reticulocyte count,
B12 and MMA level, and careful consideration of the
differential diagnosis when the LDH level is above
2500 IU/L. Patient age should be considered given thewide difference between median ages at presentation of
TTP and pseudo-TTP. Finally history of gastric bypass,
while as yet unreported as a cause of pseudo-TTP, should
alert the provider that B12 deficiency is a possible cause.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. The consent was obtained in 2014, greater than
one year following treatment and after complete recovery
of her mental state. A copy of the written consent is
available for review by the Editor of this journal.
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